Search Result

Results for "

estrogen receptor alpha (ERα)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Estrogen Receptor/ERR (118) Androgen Receptor (3) Apoptosis (18) Aryl Hydrocarbon Receptor (1) Autophagy (3) Bcl-2 Family (3) Caspase (1) COX (1) Cytochrome P450 (3) Drug Metabolite (3) Endogenous Metabolite (3) Environmental Pollutants (5) Fungal (1) Glucocorticoid Receptor (1) Glycosidase (1) Hippo (MST) (1) Insecticide (6) Isotope-Labeled Compounds (11) LDLR (1) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (3) MDM-2/p53 (1) MEK (1) Molecular Glues (1) mTOR (1) Necroptosis (3) NF-κB (1) NO Synthase (2) Parasite (3) Pregnane X Receptor (PXR) (1) PROTAC-Linker Conjugates for PAC (3) PROTACs (7) Reactive Oxygen Species (ROS) (1) Reference Standards (10) RET (1) SNIPERs (1) Sodium Channel (1) Src (1) TRP Channel (1) Wnt (1)
By Research Areas:	Cancer (114) Cardiovascular Disease (4) Endocrinology (12) Infection (8) Inflammation/Immunology (2) Metabolic Disease (6) Neurological Disease (8)

By Targets:

Estrogen Receptor/ERR (118)

Androgen Receptor (3)

Apoptosis (18)

Aryl Hydrocarbon Receptor (1)

Autophagy (3)

Bcl-2 Family (3)

Caspase (1)

COX (1)

Cytochrome P450 (3)

Drug Metabolite (3)

Endogenous Metabolite (3)

Environmental Pollutants (5)

Fungal (1)

Glucocorticoid Receptor (1)

Glycosidase (1)

Hippo (MST) (1)

Insecticide (6)

Isotope-Labeled Compounds (11)

LDLR (1)

Ligands for E3 Ligase (1)

Ligands for Target Protein for PROTAC (3)

MDM-2/p53 (1)

MEK (1)

Molecular Glues (1)

mTOR (1)

Necroptosis (3)

NF-κB (1)

NO Synthase (2)

Parasite (3)

Pregnane X Receptor (PXR) (1)

PROTAC-Linker Conjugates for PAC (3)

PROTACs (7)

Reactive Oxygen Species (ROS) (1)

Reference Standards (10)

RET (1)

SNIPERs (1)

Sodium Channel (1)

Src (1)

TRP Channel (1)

Wnt (1)

By Research Areas:

Cancer (114)

Cardiovascular Disease (4)

Endocrinology (12)

Infection (8)

Inflammation/Immunology (2)

Metabolic Disease (6)

Neurological Disease (8)

131

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: 5 alpha Reductase Estrogen Receptor/ERR IFNAR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103456

PHTPP Maximum Cited Publications 30 Publications Verification	Estrogen Receptor/ERR	Cancer
PHTPP is a selective estrogen receptor β (ERβ) antagonist with 36-fold selectivity over ERα .

HY-19822

Elacestrant 15+ Cited Publications RAD1901	Estrogen Receptor/ERR	Cancer
Elacestrant (RAD1901) is an orally available and selective **estrogen receptor degrader (SERD) with IC₅₀*s of 48 and 870 nM for ERα* and ERβ, respectively. Elacestrant also can inhibit growth of ER ⁺ breast cancer cell lines in vitro and in vivo .

HY-100689

Propyl pyrazole triol 15+ Cited Publications PPT	Estrogen Receptor/ERR	Cancer
Propyl pyrazole triol (PPT) is a selective **estrogen receptor alpha (ERα)** agonist. The relative binding affinity of Propyl pyrazole triol for ERα (ERα: 49%) around 410 times higher compared with estrogen receptor beta (ERβ: 0.12%) .

HY-B0723

Ospemifene 2 Publications Verification FC-1271a	Estrogen Receptor/ERR Caspase	Neurological Disease Endocrinology Cancer
Ospemifene (FC-1271a) is an orally active and non-estrogenic selective estrogen receptor modulator (SERM) with K_i values of 380 and 410 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene inhibits caspase-3 activity. Ospemifene inhibits neuronal degeneration, prevents bone loss, and increases vaginal weight and vaginal epithelial height. Ospemifene has anticancer activity against breast cancer .

HY-12870

AZD9496 25+ Cited Publications	Estrogen Receptor/ERR	Cancer
AZD9496 is an effective, selective estrogen receptor (ERα) antagonist with an IC₅₀ of 0.28 nM. AZD9496 is an orally active, selective estrogen receptor degrader (SERD).

HY-N0233

Bavachin Maximum Cited Publications 12 Publications Verification Corylifolin	Estrogen Receptor/ERR	Cancer
Bavachin, a flavonoid first isolated from seeds of P. corylifolia, acts as a phytoestrogen that activates the estrogen receptors ERα and ERβ with EC₅₀s of 320 and 680 nM, respectively.

HY-B0412

Estriol 5 Publications Verification Oestriol	Estrogen Receptor/ERR Endogenous Metabolite	Cancer
Estriol (Oestriol), an orally active estrogen, is a *ERα* and ERβ agonist. Estriol is a potent GPR30 antagonist in estrogen receptor-negative breast cancer cells. Estriol can ameliorate disease severity through immunomodulatory mechanisms that decrease tissue inflammation. Estriol has powerful proconvulsant effects .

HY-19822A

Elacestrant dihydrochloride 15+ Cited Publications RAD1901 dihydrochloride	Estrogen Receptor/ERR	Cancer
Elacestrant (RAD1901) dihydrochloride is an orally available and selective **estrogen receptor degrader (SERD) with IC₅₀*s of 48 and 870 nM for ERα* and ERβ, respectively. Elacestrant dihydrochloride also can inhibit growth of ER ⁺ breast cancer cell lines in vitro and in vivo .

HY-10426

XCT790 5+ Cited Publications	Estrogen Receptor/ERR Autophagy	Cancer
XCT-790 is a potent and selective inverse agonist for ERRα with an IC₅₀ value of 0.37 μM. XCT-790 induces cell death in chemotherapeutic resistant cancer cells. XCT-790 (Compound 12) is inactive against ERRγ and the estrogen receptors ERα and ERβ .

HY-103450

G36	Estrogen Receptor/ERR	Endocrinology Cancer
G-36 is a cell-permeable nonsteroidal antagonist of the G protein-coupled estrogen receptor (GPER/GPR30), which selectively inhibits estrogen-mediated PI3K activation through GPER, rather than Erα. G-36 also inhibits estrogen-mediated calcium mobilization (IC₅₀=112 nM). G-36 is promising for research in the field of cancer .

HY-15731

Estetrol	Estrogen Receptor/ERR Endogenous Metabolite NO Synthase	Cardiovascular Disease Cancer
Estetrol, an orally active estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear **estrogen receptor** modulator. Estetrol binds ERα as well as ERβ (with a fourfold lower affinity). Estetrol increases eNOS expression/activity and NO synthesis in endothelial cells. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast. Estetrol can be used in contraception and menopausal hormone research .

HY-111226

GSK5182 4 Publications Verification	Estrogen Receptor/ERR Reactive Oxygen Species (ROS)	Cardiovascular Disease Cancer
GSK5182 is a highly selective and orally active inverse agonist of estrogen-related receptor γ (ERRγ) with an IC₅₀ of 79 nM. GSK5182 does not interact with other nuclear receptors, including ERRα or ERα. GSK5182 also induces reactive oxyen species (ROS) generation in hepatocellular carcinoma (HCC) .

HY-B1662

Hexestrol 2 Publications Verification	Estrogen Receptor/ERR	Endocrinology
Hexestrol is a nonsteroidal synthetic estrogen, with a K_i of 0.06 and 0.06 nM for **estrogen receptor alpha (ERα) and ERβ*. Hexestrol can be used for the research of the diseases caused by estrogen* deficiencym, and it also can increase the weight of cattle .

HY-153468

ErSO-TFPy TEQ103; Sera2	Sodium Channel TRP Channel	Cancer
ErSO-TFPy (TEQ103) is an ERα+ tumor cell inhibitor with low nanomolar cytotoxic activity against ERα+ breast cancer cells. ErSO-TFPy activates the sodium channel TRPM4, causes an imbalance of intracellular calcium and sodium ions. ErSO-TFPy dysregulates calcium homeostasis in ERα+ tumor cells, triggers the anticipatory unfolded protein response, and induces rapid immune cell-independent necrotic cell death. ErSO-TFPy can be used for the research of estrogen receptor alpha positive breast cancer .

HY-144070

ErSO-DFP	Estrogen Receptor/ERR	Cancer
ErSO-DFP is an anticipatory unfolded protein response (a-UPR) activator. ErSO-DFP has enhanced selectivity for estrogen receptor alpha-positive (ERα+) cancer cells with a wider selectivity window than ErSO (HY-132247). ErSO-DFP displays antitumor activity against MCF-7 in mice. ErSO-DFP can cross the blood brain barrier .

HY-112100

MC-Val-Cit-PAB-PROTAC ERα Degrader-1	PROTAC-Linker Conjugates for PAC Estrogen Receptor/ERR	Cancer
MC-Val-Cit-PAB-PROTAC ERα Degrader-1 (compound LP2) consists an ADC linker and a PROTAC, whcih can be conjugated to an antibody to form PACs. MC-Val-Cit-PAB-PROTAC ERα Degrader-1 conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab) .

HY-112611

H3B-5942	Estrogen Receptor/ERR	Cancer
H3B-5942 is a selective, irreversible and orally active **estrogen receptor covalent antagonist, inactivates both wild-type and mutant ERα by targeting Cys530, with K_i*s of 1 nM and 0.41 nM, respectively. H3B-5942 reduces ERα* target gene GREB1, shows potent antitumor activity both in multiple cell lines or animals bearing ERα ^WT or ERα mutations .

HY-126109

(±)-8-Prenylnaringenin	Estrogen Receptor/ERR Apoptosis	Metabolic Disease Endocrinology Cancer
(±)-8-Prenylnaringenin, a natural prenylated flavonoid, is a potent phytoestrogen. (±)-8-Prenylnaringenin is an orally active selective estrogen receptor modulator (SERM) (Estrogen *Receptor/ERR) that inhibits ERα* and ERβ with IC₅₀s of 57 nM and 68 nM, respectively. (±)-8-Prenylnaringenin has anticancer effects, and can be used for osteoporosis research .

HY-W036120

Benzophenone-2 2,2′,4,4′-Tetrahydroxybenzophenone	Environmental Pollutants Glycosidase Estrogen Receptor/ERR Pregnane X Receptor (PXR)	Metabolic Disease Endocrinology
Benzophenone-2 (2,2',4,4'-Tetrahydroxybenzophenone) is an organic ultraviolet absorber that is widely used in personal care products and industrial products such as plastics and coatings. Benzophenone-2 is an endocrine disruptor that can interfere with estrogen receptors (ERα *receptor) and pregnane X receptor* (PXR receptor) activity, leading to reproductive toxicity, immune disorders, and metabolic abnormalities. Benzophenone-2 can inhibit the activity of α-glucosidase (IC₅₀ = 49.72 μM), and can be used for research on diabetes .

HY-N4121

Isocurcumenol 1 Publications Verification	Estrogen Receptor/ERR Apoptosis	Cancer
Isocurcumenol, an **estrogen receptor alpha (ERα)** inhibitor isolated from Curcuma zedoaria Rhizomes, possesses anti-tumor acticity, with IC₅₀ values of 99.1μg/mL and 178.2 μg/mL in DLA and KB cells, respectively .

HY-125703

Ferutinin	Estrogen Receptor/ERR Apoptosis	Infection Inflammation/Immunology Endocrinology Cancer
Ferutinin, a natural terpenoid compound, is an **estrogen receptor ERα** agonist and estrogen ERβ-receptor agonist/antagonist with IC₅₀s of 33.1 nM and 180.5 nM, respectively. Ferutinin acts as an electrogenic Ca ²⁺-ionophore that increases calcium permeability of lipid bilayer membranes, mitochondria. Ferutinin possesses estrogenic, antitumor, antibacterial and antiinflammatory activities .

HY-110157

AC-186	Estrogen Receptor/ERR	Neurological Disease
AC-186 is a selective non-steroidal estrogen receptor β (ERβ) agonist with EC₅₀s of 6 nM and 5000 nM for ERβ and ERα, respectively. AC-186 shows gender selective neuroprotective effects in a male rat model of Parkinson's disease .

HY-A0036D

Bazedoxifene acetate-D TSE-424 acetate-D	Estrogen Receptor/ERR	Cancer
Bazedoxifene (acetate)-D (TSE-424 (acetate)-D) is the D-crystal form compound of Bazedoxifene acetate (HY-A0036). Bazedoxifene acetate is an orally active, nonsteroidal selective estrogen receptor modulator (SERM), with IC₅₀s of 23 nM and 99 nM for ERα and ERβ, respectively .

HY-107835

Flumethrin FCR 2769	Environmental Pollutants Apoptosis Bcl-2 Family Parasite Insecticide	Infection Cancer
Flumethrin (FCR 2769) is a pyrethroid insecticide and acaricide . Flumethrin targets voltage-gated sodium channels and **estrogen receptor α (ERα). Flumethrin induces cytotoxicity, apoptosis**, genotoxicity and DNA damage in breast cancer cells by regulating the expression of BCL2, BAX, TP53 and P21 genes. Flumethrin is applicable to relevant studies on ectoparasite infections (tick and flea burdens) in dogs and cats, as well as breast cancer .

HY-W1006471

Estrogen receptor-agonist-1	Estrogen Receptor/ERR	Endocrinology
Estrogen receptor-agonist-1 (compound 4e) is a **estrogen receptor (ER) agonist that binds to ERα** with high affinity .

HY-112098

PROTAC ERα Degrader-1 1 Publications Verification	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERα Degrader-1 comprises an ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Degrader-1 extracts from patent WO2017201449A1, compound P1. PROTAC ERα Degrader-1 is an **estrogen receptor-alpha** (ERα) degrader.

HY-150601

Estrogen receptor-IN-1 1 Publications Verification	Estrogen Receptor/ERR	Metabolic Disease
Estrogen receptor-IN-1 (compound 16) is a potent **estrogen receptor (ER) inhibitor with IC₅₀*s of 13, 5µM for ERα* and Erβ, respectively .

HY-150803

VHL Ligand 14	Ligands for E3 Ligase	Cancer
VHL Ligand 14 (Compound 11) is a VHL ligand for design of PROTAC estrogen receptor α (ERα) degraders, with a binding affinity IC₅₀ of 196 nM .

HY-145341

GNE-149	Estrogen Receptor/ERR	Cancer
GNE-149 is an orally bioavailable full antagonist of estrogen receptor α (ERα; IC₅₀=0.053 nM). GNE-149 is a selective estrogen receptor degrader (SERD). GNE-149 can be used for the research of breast cancer .

HY-175785

X15695	Estrogen Receptor/ERR Aryl Hydrocarbon Receptor Apoptosis MDM-2/p53	Cancer
X15695 is selective and orally active estrogen receptor (ERα) degrader. X15695 is an aryl hydrocarbon receptor (AHR) ligand. X15695 enables AHR to form a complex with the ERα, promoting its proteasomal degradation. X15695 inhibits the breast cancer cells proliferation, promotes cell cycle block and induces apoptosis. X15695 can be used for the study of breast cancer .

HY-150693

Estrogen receptor β antagonist 2	Estrogen Receptor/ERR	Cancer
Estrogen receptor β antagonist 2 is a potent and selective estrogen receptor β (ERβ) antagonist with IC₅₀s of 109.10, 0.63 µM for Erα and Erβ, respectively .

HY-12870A

AZD9496 maleate 25+ Cited Publications	Estrogen Receptor/ERR	Cancer
AZD9496 maleate is a potent and selective estrogen receptor (ERα) antagonist with IC₅₀ of 0.28 nM. AZD9496 maleate is an orally bioavailable selective oestrogen receptor degrader (SERD).

HY-129619

SNIPER(ER)-87	SNIPERs Estrogen Receptor/ERR	Cancer
SNIPER(ER)-87 consists of an inhibitor of apoptosis protein (IAP) ligand LCL161 derivative that is conjugated to the estrogen receptor α (ERα) ligand 4-hydroxytamoxifen by a PEG linker, and efficiently degrades the *ERα* protein (IC₅₀=0.097 μM). SNIPER(ER)-87 preferentially recruits XIAP to ERα in the cells, and XIAP is the primary E3 ubiquitin ligase responsible for the SNIPER(ER)-87-induced ERα degradation .

HY-19822D

Elacestrant (S enantiomer) RAD1901 S enantiomer	Estrogen Receptor/ERR	Cancer
Elacestrant S enantiomer (RAD1901 S enantiomer) is an low activity enantiomer of elacestrant. Elacestrant (RAD1901) is a selective and orally available estrogen receptor (ERR) degrader with IC₅₀ values of 48 and 870 nM for ERα and ERβ, respectively .

HY-19822B

Elacestrant S enantiomer dihydrochloride RAD1901 S enantiomer dihydrochloride	Estrogen Receptor/ERR	Cancer
Elacestrant S enantiomer dihydrochloride (RAD1901 S enantiomer dihydrochloride) is an low activity enantiomer of elacestrant dihydrochloride. Elacestrant (RAD1901) dihydrochloride is a selective and orally available estrogen receptor (ERR) degrader with IC₅₀ values of 48 and 870 nM for ERα and ERβ, respectively.

HY-19498

WAY-204688 SIM-688	NF-κB	Inflammation/Immunology
WAY-204688 is an **estrogen receptor** (ER-α) selective, orally active inhibitor of NF-κB transcriptional activity with an IC₅₀ of 122 ± 30 nM for NF-κB-luciferase (NF-κB-luc) in HAECT-1 cells.

HY-128527

PROTAC ER Degrader-3	PROTAC-Linker Conjugates for PAC Estrogen Receptor/ERR	Cancer
PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab) .

HY-119418

Desketoraloxifene	Estrogen Receptor/ERR	Cancer
Desketoraloxifene is an estrogen receptors alpha (ERα) activator at an AP-1 site. Desketoraloxifene can be used for the research of osteoporosis and breast cancer .

HY-N2448

Lindleyin	Estrogen Receptor/ERR	Endocrinology
Lindleyin, isolated from Rhei rhizoma, mediates hormonal effects through estrogen receptors. Lindleyin binds to *ERα* with estrogenic activity .

HY-144733

ERα antagonist 1	Estrogen Receptor/ERR Apoptosis	Cancer
ERα antagonist 1 (Compound 19d) is a potent, selective, covalent **estrogen receptor α (ERα)** antagonist. ERα antagonist 1 induces apoptosis and cell cycle G0/G1 phase arrest in MCF-7 cells .

HY-131404

TPBM 2 Publications Verification	Estrogen Receptor/ERR	Cancer
TPBM is a potent **estrogen receptor α (ERα) inhibitor with an IC₅₀** value of 9 μM for 17β-estradiol (E2)-ERα. TPBM reduces E2·ERα recruitment to an endogenous estrogen-responsive gene. TPBM inhibits E2-dependent growth of ERα-positive cancer cells (IC₅₀=5 μM). TPBM is not toxic to cells and does not affect estrogen-independent cell growth .

HY-111484A

GDC-0927 Racemate SRN-927 Racemate	Estrogen Receptor/ERR	Cancer
GDC-0927 Racemate (SRN-927 Racemate) is an estrogen receptor (ER) degrader that can effectively inhibit the activity of *ER-α* with an IC₅₀ value of 0.2 nM and can be used in diseases related to estrogen receptors.

HY-W114419

Bisphenol C	Estrogen Receptor/ERR mTOR	Cardiovascular Disease Metabolic Disease
Bisphenol C is an **estrogen receptor-α (ERα) agonist and an ERβ antagonist, with IC₅₀** values of 2.65 nM for ERα and 1.94 nM for ERβ. Bisphenol C is a material of manufacturing polyester polymers like polycarbonate, is widely used in daily items like water bottles, food packaging, textile and so on .

HY-168869

Tamoxifen-PEG-Clozapine	PROTACs Estrogen Receptor/ERR	Cancer
Tamoxifen-PEG-Clozapine is an estrogen receptor α (ERα) PROTAC degrader. Tamoxifen-PEG-Clozapine degrades ERα via a ubiquitin-proteasome system that uses the ubiquitin protein ligase E3 component N-recognin 5. Tamoxifen-PEG-Clozapine can be used for the research of cancer . (Pink: ERα inhibitor (HY-W271653); Black: linker (HY-168870); Blue: CRBN Ligand (HY-G0021))

HY-126932

TTC-352	Estrogen Receptor/ERR	Cancer
TTC-352 is an orally bioavailable selective human estrogen receptor (ER) α partial agonist (ShERPA). TTC-352 inhibits the growth of three ER+ breast cancer cells. TTC-352 induces tumor regression accompanied by exit of *ERα* from the nucleus to extranuclear sites .

HY-132294A

(1S,3R)-GNE-502	Estrogen Receptor/ERR	Cancer
(1S,3R)-GNE-502 (compound 179) is a potent *ERα* degrader with an EC₅₀ value of 13 nM against ERα in MCF7 HCS. (1S,3R)-GNE-502 can be used to research cancer related with estrogen receptor .

HY-128528

PROTAC ER Degrader-2	PROTAC-Linker Conjugates for PAC Estrogen Receptor/ERR	Cancer
PROTAC ER Degrader-2 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab) .

HY-19822S

Elacestrant-d4 RAD1901-d₄	Isotope-Labeled Compounds Estrogen Receptor/ERR	Cancer
Elacestrant-d₄ (RAD1901-d₄) is a deuterated labeled Elacestrant (HY-19822). Elacestrant (RAD1901) is a selective estrogen receptor (estrogen *receptor, ER) degrader (SERD) with oral activity, with IC₅₀* values of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant can also effectively inhibit the growth of ER ⁺ breast cancer cell lines both in vitro and in vivo.

HY-176955

ER degrader 12	Estrogen Receptor/ERR	Cancer
ER degrader 12 (Example 1) is an estrogen receptor (ER) degrader with IC₅₀ values for *ERα* and ERβ of 2.3 and 80.2 nM respectively (TR-FRET experiment). ER degrader 12 inhibits the proliferation of MCF-7 cells, with an IC₅₀ of 1.53 nM. ER degrader 12 can be used for research on breast cancer .

HY-163680

ERα degrader 9	Estrogen Receptor/ERR Cytochrome P450	Cancer
ERα degrader 9 is a dual targeting ligand for estrogen receptor α (ERα) and aromatase (ARO). ERα degrader 9 can be utilized for synthesis of PROTAC ERα Degrader-9 (HY-163679) .

Cat. No.	Product Name	Target	Research Area

HY-P10843

R4K1	Estrogen Receptor/ERR	Cancer
R4K1 is a cell-permeable stapled peptide. R4K1 binds to the estrogen receptor (ER) α with high affinity and inhibits its interaction with coactivators. R4K1 can enter breast cancer cells to regulate gene transcription and inhibit cell proliferation. R4K1 can be used in the study of cancer .

HY-P10393

ERα17p ERα (295-311)	Apoptosis	Cancer
ERα17p (ERα 295-311) is the epitope of the CaM binding site on the estrogen receptor α (ER), which interacts with calmodulin (CaM) in a calcium-dependent manner. ERα17p regulates the migration of cancer cells MCF-7, SK-BR-3, T47D, and MDA-MB-231 through Rho/ROCK and PI3K/Akt signaling pathways. ERα17p inhibits proliferations of breast cancer cells, induces apoptosis, and inhibits tumor growth in mouse models .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0233

Bavachin Maximum Cited Publications 12 Publications Verification Corylifolin	Flavonoids Classification of Application Fields Leguminosae Flavonones Phenols Polyphenols Psoralea corylifolia L. Plants Disease Research Fields Source Classification Cancer	Estrogen Receptor/ERR
Bavachin, a flavonoid first isolated from seeds of P. corylifolia, acts as a phytoestrogen that activates the estrogen receptors ERα and ERβ with EC₅₀s of 320 and 680 nM, respectively.

HY-B0412

Estriol 5 Publications Verification Oestriol	Monophenols Immune System Disorder Classification of Application Fields Disease markers Phenols Endocrine diseases Endogenous metabolite Disease Research Fields Steroids Cancer Source Classification	Estrogen Receptor/ERR Endogenous Metabolite
Estriol (Oestriol), an orally active estrogen, is a *ERα* and ERβ agonist. Estriol is a potent GPR30 antagonist in estrogen receptor-negative breast cancer cells. Estriol can ameliorate disease severity through immunomodulatory mechanisms that decrease tissue inflammation. Estriol has powerful proconvulsant effects .

HY-15731

Estetrol	Cardiovascular Disease Monophenols Classification of Application Fields Phenols Endogenous metabolite Disease Research Fields Steroids Source Classification	Estrogen Receptor/ERR Endogenous Metabolite NO Synthase
Estetrol, an orally active estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear **estrogen receptor** modulator. Estetrol binds ERα as well as ERβ (with a fourfold lower affinity). Estetrol increases eNOS expression/activity and NO synthesis in endothelial cells. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast. Estetrol can be used in contraception and menopausal hormone research .

HY-126109

(±)-8-Prenylnaringenin	Structural Classification Flavonoids Humulus lupulus L. Flavonones Plants Moraceae Source Classification	Estrogen Receptor/ERR Apoptosis
(±)-8-Prenylnaringenin, a natural prenylated flavonoid, is a potent phytoestrogen. (±)-8-Prenylnaringenin is an orally active selective estrogen receptor modulator (SERM) (Estrogen *Receptor/ERR) that inhibits ERα* and ERβ with IC₅₀s of 57 nM and 68 nM, respectively. (±)-8-Prenylnaringenin has anticancer effects, and can be used for osteoporosis research .

HY-N4121

Isocurcumenol 1 Publications Verification	other families Classification of Application Fields Terpenoids Sesquiterpenes Plants Disease Research Fields Source Classification Cancer	Estrogen Receptor/ERR Apoptosis
Isocurcumenol, an **estrogen receptor alpha (ERα)** inhibitor isolated from Curcuma zedoaria Rhizomes, possesses anti-tumor acticity, with IC₅₀ values of 99.1μg/mL and 178.2 μg/mL in DLA and KB cells, respectively .

HY-125703

Ferutinin	Viguiera dentata (Cav.) Spreng. Infection Classification of Application Fields Terpenoids Sesquiterpenes Umbelliferae Plants Disease Research Fields Endocrinology Source Classification Cancer	Estrogen Receptor/ERR Apoptosis
Ferutinin, a natural terpenoid compound, is an **estrogen receptor ERα** agonist and estrogen ERβ-receptor agonist/antagonist with IC₅₀s of 33.1 nM and 180.5 nM, respectively. Ferutinin acts as an electrogenic Ca ²⁺-ionophore that increases calcium permeability of lipid bilayer membranes, mitochondria. Ferutinin possesses estrogenic, antitumor, antibacterial and antiinflammatory activities .

HY-N2448

Lindleyin	Classification of Application Fields Rheum palmatum L. Polygonaceae Phenols Polyphenols Plants Disease Research Fields Endocrinology Source Classification	Estrogen Receptor/ERR
Lindleyin, isolated from Rhei rhizoma, mediates hormonal effects through estrogen receptors. Lindleyin binds to *ERα* with estrogenic activity .

HY-N0233R

Bavachin (Standard) Corylifolin (Standard)	Structural Classification Flavonoids Leguminosae Flavonones Phenols Polyphenols Psoralea corylifolia L. Plants Source Classification	Reference Standards Estrogen Receptor/ERR
Bavachin (Standard) is the analytical standard of Bavachin. This product is intended for research and analytical applications. Bavachin, a flavonoid first isolated from seeds of P. corylifolia, acts as a phytoestrogen that activates the estrogen receptors ERα and ERβ with EC50s of 320 and 680 nM, respectively.

Cat. No.	Product Name	Chemical Structure

HY-19822S

Elacestrant-d4
Elacestrant-d₄ (RAD1901-d₄) is a deuterated labeled Elacestrant (HY-19822). Elacestrant (RAD1901) is a selective estrogen receptor (estrogen *receptor, ER) degrader (SERD) with oral activity, with IC₅₀* values of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant can also effectively inhibit the growth of ER ⁺ breast cancer cell lines both in vitro and in vivo.

HY-B1984S

p,p'-DDD-d8

p,p'-DDD-d₈ is the deuterium labeled p,p'-DDD[1]. p,p'-DDD (4,4’-DDD) is an organochlorine insecticide, a major metabolite of p,p'-DDT. p,p'-DDD is an agonist at estrogen receptor α(ERα) and ERβ. p,p'-DDD increases DNA damage, apoptosis and necrosis in peripheral blood. p,p'-DDD stimulates cell proliferation in SKBR3 cells. p,p'-DDD activates the AP-1 transcription factor. p,p'-DDD decreases sleep times of barbiturates and steroids in rats .

HY-B0723S2

Ospemifene-d5
Ospemifene-d₅ (FC-1271a-d₅) is deuterium labeled Ospemifene. Ospemifene is a non-estrogen selective **estrogen receptor modulator (SERM), with K_is of 380 and 410 nM for estrogen receptor α (ERα) and ERβ**, respectively. Ospemifene can be used for the research of vaginal atrophy and breast cancer .

HY-B0723S

Ospemifene-d4
Ospemifene-d₄ is a deuterium labeled Ospemifene. Ospemifene is a selective and orally active estrogen receptor modulator for the prevention of osteoporosis with IC₅₀ values of 827 nM and 1633 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene has bone-sparing, antitumor, and cholesterol-lowering effects .

HY-19822S1

Elacestrant-d4-1
Elacestrant-d₄-1 is the deuterium labeled Elacestrant (HY-19822). Elacestrant is an orally available and selective estrogen receptor degrader (SERD) with IC₅₀s of 48 and 870 nM for ERα and ERβ, respectively .

HY-19822S3

Elacestrant-d6
Elacestrant-d₆ (RAD1901-d₆) is a deuterated labeled Elacestrant (HY-19822). Elacestrant is a selective estrogen receptor (estrogen *receptor, ER) degrader (SERD) with oral activity, with IC₅₀* values of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant can also effectively inhibit the growth of ER ⁺ breast cancer cell lines both in vitro and in vivo.

HY-19822S2

Elacestrant-d10
Elacestrant-d₁₀ is the deuterium labeled of Elacestrant (HY-19822). Elacestrant is an orally available and selective **estrogen receptor degrader (SERD) with IC₅₀*s of 48 and 870 nM for ERα* and ERβ, respectively. Elacestrant also inhibits growth of ER ⁺ breast cancer cell lines in vitro and in vivo .

HY-15731S1

Estetrol-d4 (Major)

Estetrol-d₄ (Major) is the deuterium labeled Estetrol (HY-15731). Estetrol, an orally active estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear estrogen receptor modulator. Estetrol binds ERα as well as ERβ (with a fourfold lower affinity). Estetrol increases eNOS expression/activity and NO synthesis in endothelial cells. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast. Estetrol can be used in contraception and menopausal hormone research .

HY-A0031S

Bazedoxifene-d4

Bazedoxifene-d₄ is deuterium labeled Bazedoxifene. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[1][2].

HY-A0031S2

Bazedoxifene-d4 acetate

Bazedoxifene-d₄ (acetate) is the deuterium labeled Bazedoxifene[1]. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[2][3].

HY-B1662S3

Hexestrol-d4
Hexestrol-d₄ is the deuterium labeled Hexestrol (HY-B1662). Hexestrol is a nonsteroidal synthetic estrogen, with a K_i of 0.06 and 0.06 nM for estrogen receptor alpha (ERα) and ERβ. Hexestrol can be used for the research of the diseases caused by estrogen deficiencym, and it also can increase the weight of cattle .

HY-19822S4

Elacestrant-d5
Elacestrant-d₅ (RAd₁₉01-d₅) is the deuterium labeled Elacestrant (HY-19822). Elacestrant (RAD1901) is an orally available and selective **estrogen receptor degrader (SERD) with IC₅₀*s of 48 and 870 nM for ERα* and ERβ, respectively. Elacestrant also can inhibit growth of ER ⁺ breast cancer cell lines in vitro and in vivo .

HY-107835S

Flumethrin-d5

Flumethrin-d₅ (FCR 2769-d₅) is the deuterium labeled Flumethrin (HY-107835). Flumethrin (FCR 2769) is a pyrethroid insecticide and acaricide . Flumethrin targets voltage-gated sodium channels and estrogen receptor α (ERα). Flumethrin induces cytotoxicity, apoptosis, genotoxicity and DNA damage in breast cancer cells by regulating the expression of BCL2, BAX, TP53 and P21 genes. Flumethrin is applicable to relevant studies on ectoparasite infections (tick and flea burdens) in dogs and cats, as well as breast cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks